Search results for: Institute for Clinical and Economic Review (ICER)
Filter search results
Around the World in HTAs: United States – Making HTA Great Again
11 June 2024
…more important role. The Institute for Clinical and Economic Review (ICER) was founded in 2006 as a non-profit organisation conducting HTA and providing recommendations for payers about the cost-effectiveness of…
Pricing and Paying for Cures: Early Experience with HTA of Gene Therapy in the USA
28 February 2019
…challenges. In a new OHE Seminar Briefing, Dr Steven Pearson, President of the Institute for Clinical and Economic Review (ICER), discusses early experiences of using HTA to assess Gene Therapy,…
Looking Further Afield – What Can Health Economics Learn from the Environmental Economics Approach to Discounting?
1 February 2024
…R., Jones-Diette, J., Woolacott, N. and Palmer, S., 2017. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal….
Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures
1 February 2019
…of this seminar briefing is on those challenges. The Institute for Clinical and Economic Review (ICER) is an independent organisation founded in the US in 2006. Its remit is to…
New Publications: Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
18 April 2018
…real world evidence (RWE). The US Institute for Clinical and Economic Review (ICER) held a Policy Summit led by President Steve Pearson and Director of Pharmaceutical Intelligence Bill Dreitlein….
OHE Lunchtime Seminar: Early Experience with HTA of Gene Therapies in the US: Pricing and Paying for Cures
21 October 2018, 11:00pm
OHE Lunchtime Seminar with Steven Pearson, Founder and President of the Institute for Clinical and Economic Review (ICER). The time is rapidly approaching when health care funders and health care…
Cornerstones of ‘Fair’ Drug Coverage
30 September 2020
…models for pharmaceutical rebates: a report from the Institute for Clinical and Economic Review Policy Summit. J. Comp. Eff. Res. 10.2217/cer-2019-0094 C Cole, A., Towse, A., Segel C.S., Henshall, C.,…
Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
17 January 2024
…Health Economics at the CHOICE Institute, University of Washington School of Pharmacy. Meindert Boysen – Head of International Affairs at the National Institute for Health and Care Excellence (NICE). Alessandra…
A NICE Wind of Change? The What and So What of the NICE Methods Consultation
7 December 2020
…Consulting Report. London: Office of Health Economics. Zhang, K. and Garau, M., 2020. International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making. OHE Consulting Report. London: Office of Health Economics….